Noteworthy DNX finds allure in service business

If DNX Corp. (DNXX) doesn't find a partner for its core blood substitute program, it may transform itself into a different company focused on its preclinical services division, Pharmakon Research International.

Paul Schmitt, president and CEO, told BioCentury that the company's blood substitute business is responsible for a "large portion" of DNXX's $1 million per month burn rate. DNXX is developing recombinant human hemoglobin produced in transgenic